HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Expert Panel’s June Meeting: Popular Botanicals, Salicylates Among Ingredients Deemed Safe

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel issued two final safety reports and six tentative reports at its June 4-5 meeting in Washington.

You may also be interested in...



California DTSC Nominates TPHP In Nail Products As Possible Priority For Alternatives Analysis

California is taking a closer look at the safety of four potentially harmful ingredients in nail products and has named triphenyl phosphate specifically as a possible Priority Product under the state’s Safer Consumer Products regulation.

CIR Experts To Take First Look At Brown Algae Ingredients, Strategize For MI/MCI Re-Review

The Cosmetic Ingredient Review’s draft report on brown algae-derived ingredients is up for Expert Panel consideration Sept. 24-25, and five Ginkgo biloba ingredients could receive final safe-as-used sign-off. CIR also seeks the panel’s help in preparing a re-review document for the MI/MCI preservative combination, which is overdue for an updated assessment with usage up significantly since 1992.

CIR’s 2019 Priorities A Botanical Garden; AHPA To Stay Tuned In

The American Herbal Products Association vows to stay abreast of Cosmetic Ingredient Review activities, with ingredients of importance to its members sprinkled throughout the group’s 2019 priority list.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel